Kureha Kagaku Kogyo Kabushiki Kaisha

Noriyuki Toyoda

Chikao Yoshikumi

Kenichi Matsunaga

Takayoshi Fujii

Takao Furusho

Masanori Ikuzawa

Yoshiharu Oguchi

Takao Ando

Yuji Maeda

Toshihiko Wada

Tadaaki Kato

Hideyuki Yamato

Yoshio Omura

Hiromitsu Makita

Disclosed herein is a pharmaceutical composition having antirheumatic activity, antithrombotic activity, analgetic activity, antipyretics activity, anti-hyperlipemic activity and anti-inflammatory activity and activities of reducing the level of blood sugar, raising the coronary blood flow, improving the capability of deformation of erythrocytes, reducing the blood pressure, ameliorating proteinuria and proteinemia and regulating production or metabolism of prostaglandins in a mammal in dosage unit form, which comprises a dosage effective to produce said activities of a glycoprotein having a molecular weight of 5000 to 300,000 as determined by ultracentrifugal method and about 18 to 38% by weight of proteins, produced by culturing a basidiomycetous fungal species belonging to the genus Coriolus, extracting the thus proliferated mycelia or fruit bodies with hot water or aqueous alkali solution and removing low molecular weight substances having a molecular weight of less than 5000 from the extract.

Pharmaceutical composition containing a glycoprotein

Disclosed herein is a pharmaceutical composition having antirheumatic activity, antithrombotic activity, analgetic activity, antipyretic activity, anti-hyperlipemic activity and anti-inflammatory activity and activities of reducing the level of blood sugar, raising the coronary blood flow, improving the capability of deformation of erythrocytes, reducing the blood pressure, ameliorating proteinuria and proteinemia and regulating production or metabolism of prostaglandins in a mammal in dosage unit form, which comprises a dosage effective to produce said activities of a glycoprotein having a molecular weight of 5000 to 300000 as determined by ultracentrifugal method and about 18 to 38% by weight of proteins, produced by culturing a basidiomycetous fungal species belonging to the genus Coriolus, extracting the thus proliferated mycelia or fruit bodies with hot water or aqueous alkali solution and removing low molecular weight substances having a molecular weight of less than 5000 from the extract.

Disclosed is a pharmaceutical composition in dosage unit form which comprises a dosage effective for the treatment of myodystrophia of a compound of 24,25-dihydroxycholecalciferol and a pharmaceutical acceptable carrier or diluent therefor.

Pharmaceutical composition containing 24,25-dihydroxycholecalciferol as

The Basidiomycetes belonging to the genus Coriolus of family Polyporaceae are cultivated by using a glucose-yeast extract medium with the mixed ratio of glucose to yeast extract being within a specified range to improve the yield of mycelia obtained by the cultivation.

Method for the cultivation of Basidiomycetes belonging to the genus

When a dikaryotic mycelium of Coriolus versicolor (Fr.) Quel. (a species of fungi belonging to the genus Coriolus of Polyporaceae) is subjected to a mechanical treatment such as grinding or shearing in a liquid medium, or when such mycelium is subjected to submerged culture while undergoing mechanical treatment, there is produced a monokaryotic mycelium which is different from the dikaryotic mycelium in morphological and physiological characteristics. The thus obtained monokaryotic mycelium is a novel product and characterized by its extremely high propagation rate as compared with the known dikaryotic mycelium. Also, the substance extracted from the culture of the mycelium has excellent physiological activities.

Growing community of inventors

Sagamihara, Japan

Noriyuki Toyoda